Bank of New York Mellon Corp Buys 29,319 Shares of CytomX Therapeutics, Inc. (CTMX)
Bank of New York Mellon Corp increased its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 33.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 115,777 shares of the biotechnology company’s stock after acquiring an additional 29,319 shares during the period. Bank of New York Mellon Corp owned approximately 0.32% of CytomX Therapeutics worth $1,794,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $325,000. Rhumbline Advisers lifted its position in CytomX Therapeutics by 48.4% during the 2nd quarter. Rhumbline Advisers now owns 32,517 shares of the biotechnology company’s stock worth $504,000 after acquiring an additional 10,607 shares in the last quarter. Foundry Partners LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $1,186,000. Schwab Charles Investment Management Inc. lifted its position in CytomX Therapeutics by 17.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 117,642 shares of the biotechnology company’s stock worth $1,824,000 after acquiring an additional 17,551 shares in the last quarter. Finally, Algert Global LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $539,000. 59.97% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) opened at 20.50 on Tuesday. The firm’s 50-day moving average price is $18.43 and its 200 day moving average price is $15.80. The stock’s market capitalization is $755.77 million. CytomX Therapeutics, Inc. has a 12-month low of $9.85 and a 12-month high of $24.67.
CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. Analysts predict that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current fiscal year.
Several research firms recently commented on CTMX. Wedbush began coverage on CytomX Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $26.00 price target on the stock. Cann reissued a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. BidaskClub lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Finally, Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, June 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. CytomX Therapeutics currently has an average rating of “Hold” and a consensus price target of $31.43.
TRADEMARK VIOLATION NOTICE: This article was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://theolympiareport.com/2017/10/17/bank-of-new-york-mellon-corp-buys-29319-shares-of-cytomx-therapeutics-inc-ctmx.html.
In related news, CEO Sean A. Mccarthy sold 19,120 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $24.13, for a total transaction of $461,365.60. Following the completion of the sale, the chief executive officer now owns 23,365 shares in the company, valued at approximately $563,797.45. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sean A. Mccarthy sold 4,781 shares of the stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total value of $71,715.00. Following the sale, the insider now owns 9,026 shares of the company’s stock, valued at approximately $135,390. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 177,794 shares of company stock valued at $3,806,089. 8.00% of the stock is owned by corporate insiders.
CytomX Therapeutics Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.